Onconic Therapeutics has projected that, based on the commercial performance of its directly approved new drug “Zacubo,” it will post sales of 111.8 billion won and operating profit of 26.5 billion won this year.


In a disclosure on the 5th, the company stated this outlook and evaluated it by saying, “Compared with last year’s sales of 53.4 billion won and operating profit of 12.6 billion won, this represents an increase of nearly twofold, showing that a structure in which a commercialized new drug directly drives performance has rapidly taken hold from immediately after listing.” These figures significantly exceed the estimates presented in the securities registration statement at the time of listing, surpassing market expectations.


Onconic Therapeutics Forecasts 111.8 Billion Won in Sales and 26.5 Billion Won in Operating Profit This Year View original image

In the domestic bio industry, there have been cases in which earnings surged in a short period due to one-off milestone income from technology transfer agreements. However, analysts say Onconic Therapeutics’ latest earnings outlook is differentiated in that, from the early stage of its technology-special listing, it has been generating large-scale sales and operating profit every year on a stable basis and maintaining high growth, which remains a rare case.


The core driver of growth is “Zacubo,” the 37th domestically developed new drug and a treatment for gastroesophageal reflux disease, which competes in a global market estimated at about 40 trillion won. Since its launch in October 2024, Zacubo has quickly established itself in the prescription market. According to outpatient prescription data from UBIST, Zacubo’s monthly prescription value expanded from about 500 million won in its first month on the market to about 6.6 billion won as of December last year, marking 13-fold growth in roughly one year. Its quarterly prescription volume has also shown an expanding increase each quarter, and within just one year it has secured a position as a key product in the gastroesophageal reflux disease treatment market, demonstrating its potential to grow into a global blockbuster drug.


This year, the launch of an orally disintegrating tablet (ODT) formulation and the addition of a new indication for gastric ulcers are expected to expand both dosing convenience and the range of prescriptions. The company explained that these factors are the main reasons it expects this year’s sales to grow to nearly double those of the previous year.


Results are also becoming visible in overseas markets. Under its technology transfer agreement with China’s Livzon, Onconic Therapeutics has completed Phase 3 clinical trials and is proceeding with the marketing authorization process, while milestone income tied to the contract terms is being recognized sequentially.


While Zacubo is being evaluated as a major new drug expected to generate more than 100 billion won in annual domestic sales this year, its launch in the Chinese market, which is worth about 6 trillion won, is anticipated around the end of the year. There is growing discussion that this could mark the first year of its leap into a global blockbuster. For these reasons, the industry expects that in 2027, when Zacubo begins to generate full-fledged sales in overseas markets, Onconic Therapeutics will be able to continue high growth in earnings that surpasses its 2026 sales.


Meanwhile, Onconic Therapeutics is also focusing on research and development of next-generation anticancer drugs, backed by the cash-generating base it has secured through new drug commercialization. The next-generation synthetic lethal dual-target anticancer drug Nesuparib is simultaneously undergoing Phase 2 clinical trials in a total of four indications: pancreatic cancer, ovarian cancer, endometrial cancer, and gastric cancer, having already confirmed safety and some antitumor activity in Phase 1.


In this regard, the securities industry projects that, following Zacubo, which is aiming to become a global blockbuster, the corporate value of Onconic Therapeutics could be significantly re-rated depending on the development results of Nesuparib, which is in Phase 2 trials for four cancer types with large areas of unmet global medical need.


Onconic Therapeutics, which is pursuing the successful model of Gilead Sciences—securing R&D funding through stable revenue after its first new drug commercialization and then growing via follow-up new drug development—is drawing strong market attention with this earnings outlook disclosure. This is because the company is maintaining a structure in which it generates a meaningful operating profit of 26.5 billion won this year while simultaneously conducting anticancer drug R&D.



A representative of Onconic Therapeutics said, “The gastroesophageal reflux disease market is a large-scale market that rivals the obesity treatment market, and Zacubo’s global growth potential is very high,” adding, “Building on our direct approval experience with Zacubo, we are rapidly advancing the development of Nesuparib, and this year we will continue to enhance our corporate value through achievements in anticancer new drugs.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing